GLP-1 weight regain after stopping: what the data actually shows

What did @jclarke_fitness actually say?

The creator's core claim is that stopping GLP-1 medications like semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), or liraglutide leads to significant weight regain, specifically "50 to 60% of the weight they lost within the first year." They also argue that people who keep the weight off long-term are the ones who pair medication with a high-protein diet, strength training, and consistent habits.

To their credit, they're not selling a supplement or telling people to quit their meds cold turkey. The message is essentially: the drug lowers your appetite, but it doesn't rewire your habits permanently. That framing is more honest than a lot of what circulates in the weight loss corner of TikTok.

But the 50-60% figure deserves scrutiny. A specific statistic like that needs a specific source, and the creator doesn't provide one.

Does the science back this up?

Yes, broadly. The weight regain data after stopping GLP-1 drugs is real, well-documented, and honestly pretty sobering. The STEP 4 trial (Rubino et al., 2021, JAMA) is the landmark reference here. Participants who stopped semaglutide after 20 weeks regained about two-thirds of their prior weight loss within a year of discontinuation. That's actually worse than the 50-60% figure the creator cites.

The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) produced similar findings for tirzepatide. Participants who switched to placebo after 36 weeks on tirzepatide regained roughly half the weight they'd lost, while those who stayed on the drug continued to lose.

The biological mechanism is real too. GLP-1 receptors in the hypothalamus regulate appetite signaling. When the drug is removed, that suppression lifts. Hunger returns, often to baseline or above, because the underlying physiology driving appetite hasn't changed. This is sometimes called "rebound hyperphagia" in the literature, though the evidence on that specific term is still developing.

What did they get wrong (or right)?

The 50-60% figure is on the conservative side compared to what the STEP 4 data actually shows. In that trial, participants regained approximately 6.9 kg out of 9.6 kg lost, which is closer to 70%. So the creator may actually be underselling how significant regain can be. That said, individual variation is real, and different drugs, doses, and durations produce different outcomes, so calling it "50 to 60%" isn't reckless.

Where the creator earns credit is on the behavioral piece. The claim that people who keep weight off long-term "don't rely solely on the meds" is consistent with what clinicians and researchers actually observe. A 2022 analysis in Obesity Reviews (Dombrowski et al.) found that structured behavioral interventions alongside pharmacotherapy produced more durable outcomes than medication alone.

The three recommendations, specifically protein intake, resistance training, and habit consistency, are all evidence-based. None of them are harmful. None of them are fringe. They're just good advice.

One thing that's missing from the video: the creator doesn't mention that for many people, these medications may need to be taken long-term, the same way someone manages blood pressure or cholesterol with ongoing medication. Framing discontinuation as the default outcome, without addressing that option, is an incomplete picture.

What should you actually know?

GLP-1 receptor agonists appear to work best as part of an ongoing treatment strategy, not a short course you complete and then stop. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained weight loss over two years with continued semaglutide use. The drugs are not a "reset button" you can press and walk away from.

If you're considering stopping a GLP-1 medication, that decision should involve your prescribing provider. The question isn't just "will I regain weight" but "what support structures are in place if I do." Protein intake and strength training genuinely help preserve muscle mass during weight loss phases, which matters for metabolic health independent of the scale number.

Compounded semaglutide and compounded tirzepatide are not the same as FDA-approved branded formulations. If you're using a compounded version, the clinical data from STEP and SURMOUNT trials does not directly apply to your product. That's a gap worth understanding before making decisions based on those study outcomes.